Posted by Ritch on August 7, 2002, at 9:39:50
In reply to Interesting article, posted by Anyuser on August 6, 2002, at 17:58:28
> Here is a link to an article in BusinessWeek about Forrest Laboratories, the makers of Celexa and Lexapro. The founder of Forrest Labs is the father of Andrew Solomon, the author of The Noonday Demon.
>
> http://www.businessweek.com/magazine/content/02_21/b3784001.htm
Yes, that was indeed very interesting. It would be nice if more pharm. companies would be interested in attempting to market meds that are already available in other countries that could be helpful here. I am thinking of moclobemide for one (why doesn't Roche try to get FDA approval here?). Also, the active metabolite of nortriptyline (I think E-10 OH-nortriptyline), has good anxiolytic properties, downregulates 5-HT receptors, and has nil side effects (that TCA's typically have). Why can't that be developed? Marketing active metabolits of older drugs is becoming more common (fexofenadine and cetirizine, ie.).Mitch
poster:Ritch
thread:109458
URL: http://www.dr-bob.org/babble/20020807/msgs/115535.html